Ji Xing is developing best-in-class medicines in China.
Our vision is to bring some of the most innovative therapeutics in the industry to underserved Chinese patients. We strive to leverage drug development to help these patients live longer and healthier lives.
Ji Xing is developing best-in-class treatments for serious and life-threatening diseases. Ji Xing’s lead program is an investigational, oral, novel small molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy in-licensed from Cytokinetics (CK-274).
Ji Xing believes in great science and collaborations with world-class institutions. Please contact us for China territory partnering opportunities.
Proven Leadership Team
We are a global team with deep expertise in drug development and commercialization in China. We have a distinguished track record of executing and delivering for our partners, and most importantly, for patients.
Culture of Innovation
Here at Ji Xing, we recognize that our culture is our greatest asset. Our people are committed to patients, science, and working together as a team to develop and commercialize great medicines.
Oct 18, 2021
Aug 6, 2021
Aug 5, 2021
Jul 13, 2021
May 17, 2021
Jul 14, 2020